In patients with primary cutaneous melanoma, this study was undertaken to investigate if histologically confirmed regression was correlated with better or worse survival.
Publications
Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common and difficult-to-treat form of eye cancer — the company announced in a press release.
The Paradoxical Behavior of microRNA-211 in Melanomas and Other Human Cancers
Cancer initiation, progression, and metastasis leverage many regulatory agents, such as signaling molecules, transcription factors, and regulatory RNA molecules.
Impact of the time interval between primary melanoma excision and sentinel node biopsy: A systematic review and meta-analysis
Researchers conducted this systematic review and meta-analysis to assess the connection between time from biopsy to sentinel-node biopsy (SLNB) and patients’ outcomes for melanoma.